FDA approves new therapy for double-positive metastatic breast cancer
 

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with "double-positive" metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.

More...